Total Valuation
Basilea Pharmaceutica has a market cap or net worth of $992.12M. The enterprise value is $644.92.
Market Cap$992.12M
Enterprise Value$644.92
Share Statistics
Basilea Pharmaceutica has 13,440,478 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,440,478
Owned by Insiders―
Owned by Institutions0.11%
Financial Efficiency
Basilea Pharmaceutica’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 19.29%.
Return on Equity (ROE)0.31
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)19.29%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee1.16M
Profits Per Employee201.20K
Employee Count200
Asset Turnover0.82
Inventory Turnover1.82
Valuation Ratios
The current PE Ratio of Basilea Pharmaceutica is 16.2. Basilea Pharmaceutica’s PEG ratio is -0.34.
PE Ratio16.2
PS Ratio2.88
PB Ratio5.22
Price to Fair Value5.22
Price to FCF11.28
Price to Operating Cash Flow14.71
PEG Ratio-0.34
Income Statement
In the last 12 months, Basilea Pharmaceutica had revenue of 232.40M and earned 40.20M in profits. Earnings per share was 3.29.
Revenue232.40M
Gross Profit193.10M
Operating Income51.60M
Pretax Income45.90M
Net Income40.20M
EBITDA55.26M
Earnings Per Share (EPS)3.29
Cash Flow
In the last 12 months, operating cash flow was 58.01M and capital expenditures -2.71M, giving a free cash flow of 55.30M billion.
Operating Cash Flow58.01M
Free Cash Flow55.30M
Free Cash Flow per Share4.11
Dividends & Yields
Basilea Pharmaceutica pays an annual dividend of $5.38, resulting in a dividend yield of 4.02%
Dividend Per Share$5.38
Dividend Yield4.02%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.02
52-Week Price Change43.54%
50-Day Moving Average70.90
200-Day Moving Average68.34
Relative Strength Index (RSI)65.15
Average Volume (3m)3.00
Important Dates
Basilea Pharmaceutica upcoming earnings date is Feb 16, 2027, TBA (Confirmed).
Last Earnings DateAug 18, 2026
Next Earnings DateFeb 16, 2027
Ex-Dividend Date―
Financial Position
Basilea Pharmaceutica as a current ratio of 5.11, with Debt / Equity ratio of 51.40%
Current Ratio5.11
Quick Ratio4.68
Debt to Market Cap0.11
Net Debt to EBITDA1.08
Interest Coverage Ratio15.37
Taxes
In the past 12 months, Basilea Pharmaceutica has paid 5.60M in taxes.
Income Tax5.60M
Effective Tax Rate0.12
Enterprise Valuation
Basilea Pharmaceutica EV to EBITDA ratio is 13.17, with an EV/FCF ratio of 12.29.
EV to Sales3.13
EV to EBITDA13.17
EV to Free Cash Flow12.29
EV to Operating Cash Flow11.72
Balance Sheet
Basilea Pharmaceutica has $175.98M in cash and marketable securities with $83.44M in debt, giving a net cash position of $92.54M billion.
Cash & Marketable Securities$175.98M
Total Debt$83.44M
Net Cash$92.54M
Net Cash Per Share$6.88
Tangible Book Value Per Share$10.44
Margins
Gross margin is 87.67%, with operating margin of 22.20%, and net profit margin of 17.30%.
Gross Margin87.67%
Operating Margin22.20%
Pretax Margin19.75%
Net Profit Margin17.30%
EBITDA Margin23.78%
EBIT Margin22.20%
Analyst Forecast
The average price target for Basilea Pharmaceutica is $133.40, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$133.40
Price Target Upside71.95% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast14.52%
EPS Growth Forecast-22.07%